Alere increases Axis-Shield stake to 81%; plans to delist shares
This article was originally published in Clinica
Executive Summary
Alere plans to delist Axis-Shield from the London Stock Exchange and Oslo Bors, as it continues to make inroads into its takeover of the Anglo-Nordic firm. At the close of business on Friday, Alere had almost 81% of Axis-Shield.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: